



Clinical trial results:

Phase II study to assess bacterial count reduction of three Octenidine mouthwash concentrations in comparison to a placebo in patients with mild gingivitis

Summary

| | |
|--------------------------|------------------|
| EudraCT number | 2013-002708-14 |
| Trial protocol | DE |
| Global end of trial date | 17 February 2014 |

Results information

| | |
|--------------------------------|-------------------|
| Result version number | v1 (current) |
| This version publication date | 09 September 2021 |
| First version publication date | 09 September 2021 |

Trial information

Trial identification

| | |
|-----------------------|---------|
| Sponsor protocol code | OML0113 |
|-----------------------|---------|

Additional study identifiers

| | |
|------------------------------------|---|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | - |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|--|
| Sponsor organisation name | Schülke & Mayr GmbH |
| Sponsor organisation address | Robert-Koch-Straße 2, Norderstedt, Germany, 22851 |
| Public contact | Clinical trials information, Schülke & Mayr GmbH, 49 40521000, info@schuelke.com |
| Scientific contact | Clinical trials information, Schülke & Mayr GmbH, 49 40521000, info@schuelke.com |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|------------------|
| Analysis stage | Final |
| Date of interim/final analysis | 17 February 2014 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 17 February 2014 |
| Global end of trial reached? | Yes |
| Global end of trial date | 17 February 2014 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

To identify the most efficacious octenidine dihydrochloride concentration regarding bacterial count reduction in comparison to placebo

Protection of trial subjects:

Not applicable

Background therapy: -

Evidence for comparator: -

| | |
|---|-----------------|
| Actual start date of recruitment | 28 October 2013 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|-------------|
| Country: Number of subjects enrolled | Germany: 90 |
| Worldwide total number of subjects | 90 |
| EEA total number of subjects | 90 |

Notes:

Subjects enrolled per age group

| | |
|---|----|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 88 |
| From 65 to 84 years | 2 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details:

Patients were recruited at 2 clinical sites in Germany. The first patient was recruited on 28 Oct 2013 and the last patient on 7 Jan 2014.

Pre-assignment

Screening details:

105 patients were screened; 15 of which were not randomised because they did not meet the eligibility criteria.

Period 1

| | |
|------------------------------|--|
| Period 1 title | Period 1 |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Investigator, Monitor, Data analyst, Assessor, Subject |

Arms

| | |
|------------------------------|-----------------------|
| Are arms mutually exclusive? | Yes |
| Arm title | OML 0.1% then placebo |

Arm description:

Treatment with OML 0.1% in Period 1, followed by placebo in Period 2

| | |
|--|---------------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Octenidine dihydrochloride 0.1% |
| Investigational medicinal product code | OML |
| Other name | |
| Pharmaceutical forms | Oromucosal solution |
| Routes of administration | Oromucosal use |

Dosage and administration details:

Use of study drug twice daily (rinsing the oral cavity with 10 mL study drug for 30 s) over a period of 4.5 days.

| | |
|------------------|-----------------------|
| Arm title | Placebo then OML 0.1% |
|------------------|-----------------------|

Arm description:

Treatment with placebo in Period 1, followed by OML 0.1% in Period 2

| | |
|--|---------------------|
| Arm type | Placebo |
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Oromucosal solution |
| Routes of administration | Oromucosal use |

Dosage and administration details:

Use of study drug twice daily (rinsing the oral cavity with 10 mL study drug for 30 s) over a period of 4.5 days.

| | |
|------------------|------------------------|
| Arm title | OML 0.15% then placebo |
|------------------|------------------------|

Arm description:

Treatment with OML 0.15% in Period 1, followed by placebo in Period 2

| | |
|----------|--------------|
| Arm type | Experimental |
|----------|--------------|

| | |
|--|----------------------------------|
| Investigational medicinal product name | Octenidine dihydrochloride 0.15% |
| Investigational medicinal product code | OML |
| Other name | |
| Pharmaceutical forms | Oromucosal solution |
| Routes of administration | Oromucosal use |

Dosage and administration details:

Use of study drug twice daily (rinsing the oral cavity with 10 mL study drug for 30 s) over a period of 4.5 days.

| | |
|------------------|------------------------|
| Arm title | Placebo then OML 0.15% |
|------------------|------------------------|

Arm description:

Treatment with placebo in Period 1, followed by OML 0.15% in Period 2

| | |
|--|---------------------|
| Arm type | Placebo |
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Oromucosal solution |
| Routes of administration | Oromucosal use |

Dosage and administration details:

Use of study drug twice daily (rinsing the oral cavity with 10 mL study drug for 30 s) over a period of 4.5 days.

| | |
|------------------|-----------------------|
| Arm title | OML 0.2% then placebo |
|------------------|-----------------------|

Arm description:

Treatment with OML 0.2% in Period 1, followed by placebo in Period 2

| | |
|--|---------------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Octenidine dihydrochloride 0.2% |
| Investigational medicinal product code | OML |
| Other name | |
| Pharmaceutical forms | Oromucosal solution |
| Routes of administration | Oromucosal use |

Dosage and administration details:

Use of study drug twice daily (rinsing the oral cavity with 10 mL study drug for 30 s) over a period of 4.5 days.

| | |
|------------------|-----------------------|
| Arm title | Placebo then OML 0.2% |
|------------------|-----------------------|

Arm description:

Treatment with placebo in Period 1, followed by OML 0.2% in Period 2

| | |
|--|---------------------|
| Arm type | Placebo |
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Oromucosal solution |
| Routes of administration | Oromucosal use |

Dosage and administration details:

Use of study drug twice daily (rinsing the oral cavity with 10 mL study drug for 30 s) over a period of 4.5 days.

| Number of subjects in period 1 | OML 0.1% then placebo | Placebo then OML 0.1% | OML 0.15% then placebo |
|---------------------------------------|-----------------------|-----------------------|------------------------|
| Started | 14 | 15 | 15 |
| Completed | 14 | 15 | 15 |

| Number of subjects in period 1 | Placebo then OML 0.15% | OML 0.2% then placebo | Placebo then OML 0.2% |
|---------------------------------------|------------------------|-----------------------|-----------------------|
| Started | 15 | 16 | 15 |
| Completed | 15 | 16 | 15 |

Period 2

| | |
|------------------------------|--|
| Period 2 title | Period 2 |
| Is this the baseline period? | No |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Subject, Investigator, Monitor, Data analyst, Assessor |

Arms

| | |
|------------------------------|-----|
| Are arms mutually exclusive? | Yes |
|------------------------------|-----|

| | |
|------------------|-----------------------|
| Arm title | OML 0.1% then placebo |
|------------------|-----------------------|

Arm description:

Treatment with OML 0.1% in Period 1, followed by placebo in Period 2

| | |
|--|---------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Oromucosal solution |
| Routes of administration | Oromucosal use |

Dosage and administration details:

Use of study drug twice daily (rinsing the oral cavity with 10 mL study drug for 30 s) over a period of 4.5 days.

| | |
|------------------|-----------------------|
| Arm title | Placebo then OML 0.1% |
|------------------|-----------------------|

Arm description:

Treatment with placebo in Period 1, followed by OML 0.1% in Period 2

| | |
|--|---------------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Octenidine dihydrochloride 0.1% |
| Investigational medicinal product code | OML |
| Other name | |
| Pharmaceutical forms | Oromucosal solution |
| Routes of administration | Oromucosal use |

Dosage and administration details:

Use of study drug twice daily (rinsing the oral cavity with 10 mL study drug for 30 s) over a period of 4.5 days.

| | |
|------------------|------------------------|
| Arm title | OML 0.15% then placebo |
|------------------|------------------------|

| | |
|---|------------------------|
| Arm description: | |
| Treatment with OML 0.15% in Period 1, followed by placebo in Period 2 | |
| Arm type | Experimental |
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Oromucosal solution |
| Routes of administration | Oromucosal use |
| Dosage and administration details: | |
| Use of study drug twice daily (rinsing the oral cavity with 10 mL study drug for 30 s) over a period of 4.5 days. | |
| Arm title | Placebo then OML 0.15% |

| | |
|---|----------------------------------|
| Arm description: | |
| Treatment with placebo in Period 1, followed by OML 0.15% in Period 2 | |
| Arm type | Experimental |
| Investigational medicinal product name | Octenidine dihydrochloride 0.15% |
| Investigational medicinal product code | OML |
| Other name | |
| Pharmaceutical forms | Oromucosal solution |
| Routes of administration | Oromucosal use |
| Dosage and administration details: | |
| Use of study drug twice daily (rinsing the oral cavity with 10 mL study drug for 30 s) over a period of 4.5 days. | |
| Arm title | OML 0.2% than placebo |

| | |
|---|-----------------------|
| Arm description: | |
| Treatment with OML 0.5% in Period 1, followed by placebo in Period 2 | |
| Arm type | Experimental |
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Oromucosal solution |
| Routes of administration | Oromucosal use |
| Dosage and administration details: | |
| Use of study drug twice daily (rinsing the oral cavity with 10 mL study drug for 30 s) over a period of 4.5 days. | |
| Arm title | Placebo then OML 0.2% |

| | |
|---|---------------------------------|
| Arm description: | |
| Treatment with placebo in Period 1, followed by OML 0.2% in Period 2 | |
| Arm type | Experimental |
| Investigational medicinal product name | Octenidine dihydrochloride 0.2% |
| Investigational medicinal product code | OML |
| Other name | |
| Pharmaceutical forms | Oromucosal solution |
| Routes of administration | Oromucosal use |
| Dosage and administration details: | |
| Use of study drug twice daily (rinsing the oral cavity with 10 mL study drug for 30 s) over a period of 4.5 days. | |

| Number of subjects in period 2 | OML 0.1% then placebo | Placebo then OML 0.1% | OML 0.15% then placebo |
|---------------------------------------|-----------------------|-----------------------|------------------------|
| Started | 14 | 15 | 15 |
| Completed | 14 | 15 | 15 |

| Number of subjects in period 2 | Placebo then OML 0.15% | OML 0.2% than placebo | Placebo then OML 0.2% |
|---------------------------------------|------------------------|-----------------------|-----------------------|
| Started | 15 | 16 | 15 |
| Completed | 15 | 16 | 15 |

Baseline characteristics

Reporting groups

| | |
|-----------------------|----------|
| Reporting group title | Period 1 |
|-----------------------|----------|

Reporting group description: -

| Reporting group values | Period 1 | Total | |
|---------------------------------------|----------|-------|--|
| Number of subjects | 90 | 90 | |
| Age categorical Units: Subjects | | | |
| Adults (18-64 years) | 88 | 88 | |
| From 65-84 years | 2 | 2 | |
| Age continuous Units: years | | | |
| arithmetic mean | 28.4 | | |
| standard deviation | ± 10.9 | - | |
| Gender categorical Units: Subjects | | | |
| Female | 58 | 58 | |
| Male | 32 | 32 | |

End points

End points reporting groups

| | |
|---|------------------------|
| Reporting group title | OML 0.1% then placebo |
| Reporting group description: | |
| Treatment with OML 0.1% in Period 1, followed by placebo in Period 2 | |
| Reporting group title | Placebo then OML 0.1% |
| Reporting group description: | |
| Treatment with placebo in Period 1, followed by OML 0.1% in Period 2 | |
| Reporting group title | OML 0.15% then placebo |
| Reporting group description: | |
| Treatment with OML 0.15% in Period 1, followed by placebo in Period 2 | |
| Reporting group title | Placebo then OML 0.15% |
| Reporting group description: | |
| Treatment with placebo in Period 1, followed by OML 0.15% in Period 2 | |
| Reporting group title | OML 0.2% then placebo |
| Reporting group description: | |
| Treatment with OML 0.2% in Period 1, followed by placebo in Period 2 | |
| Reporting group title | Placebo then OML 0.2% |
| Reporting group description: | |
| Treatment with placebo in Period 1, followed by OML 0.2% in Period 2 | |
| Reporting group title | OML 0.1% then placebo |
| Reporting group description: | |
| Treatment with OML 0.1% in Period 1, followed by placebo in Period 2 | |
| Reporting group title | Placebo then OML 0.1% |
| Reporting group description: | |
| Treatment with placebo in Period 1, followed by OML 0.1% in Period 2 | |
| Reporting group title | OML 0.15% then placebo |
| Reporting group description: | |
| Treatment with OML 0.15% in Period 1, followed by placebo in Period 2 | |
| Reporting group title | Placebo then OML 0.15% |
| Reporting group description: | |
| Treatment with placebo in Period 1, followed by OML 0.15% in Period 2 | |
| Reporting group title | OML 0.2% than placebo |
| Reporting group description: | |
| Treatment with OML 0.5% in Period 1, followed by placebo in Period 2 | |
| Reporting group title | Placebo then OML 0.2% |
| Reporting group description: | |
| Treatment with placebo in Period 1, followed by OML 0.2% in Period 2 | |
| Subject analysis set title | OML 0.1%, OML period |
| Subject analysis set type | Intention-to-treat |
| Subject analysis set description: | |
| This analysis set included all patients receiving either OML 0.1% in Period 1 followed by placebo in Period 2, or placebo in Period 1 followed by OML 0.1% in Period 2. Data are included for the OML period. | |
| Subject analysis set title | OML 0.15%; OML period |
| Subject analysis set type | Intention-to-treat |
| Subject analysis set description: | |
| This analysis set included all patients receiving either OML 0.15% in Period 1 followed by placebo in Period 2, or placebo in Period 1 followed by OML 0.15% in Period 2. Data are included for the OML period. | |
| Subject analysis set title | OML 0.2%; OML period |

| | |
|--|---------------------------|
| Subject analysis set type | Intention-to-treat |
| Subject analysis set description: This analysis set included all patients receiving either OML 0.2% in Period 1 followed by placebo in Period 2, or placebo in Period 1 followed by OML 0.2% in Period 2. Data are included for the OML period. | |
| Subject analysis set title | OML 0.1%; placebo period |
| Subject analysis set type | Intention-to-treat |
| Subject analysis set description: This analysis set included all patients receiving either OML 0.1% in Period 1 followed by placebo in Period 2, or placebo in Period 1 followed by OML 0.1% in Period 2. Data from the placebo period are included. | |
| Subject analysis set title | OML 0.15%; placebo period |
| Subject analysis set type | Intention-to-treat |
| Subject analysis set description: This analysis set included all patients receiving either OML 0.15% in Period 1 followed by placebo in Period 2, or placebo in Period 1 followed by OML 0.15% in Period 2. Data are included for the placebo period. | |
| Subject analysis set title | OML 0.2%; placebo period |
| Subject analysis set type | Intention-to-treat |
| Subject analysis set description: This analysis set included all patients receiving either OML 0.2% in Period 1 followed by placebo in Period 2, or placebo in Period 1 followed by OML 0.2% in Period 2. Data are included for the placebo period. | |
| Subject analysis set title | Placebo |
| Subject analysis set type | Intention-to-treat |
| Subject analysis set description: Patients receiving placebo | |
| Subject analysis set title | OML 0.1% |
| Subject analysis set type | Intention-to-treat |
| Subject analysis set description: Patients receiving OML 0.15% | |
| Subject analysis set title | OML 0.15% |
| Subject analysis set type | Intention-to-treat |
| Subject analysis set description: Patients receiving OML 0.15% | |
| Subject analysis set title | OML 0.20% |
| Subject analysis set type | Intention-to-treat |
| Subject analysis set description: Patients receiving OML 0.2% | |

Primary: Bacterial count reduction factor in saliva

| | |
|---|--|
| End point title | Bacterial count reduction factor in saliva |
| End point description: The bacterial count reduction factor in saliva was defined as the absolute difference in log ₁₀ values of bacterial counts before and 1 min after rinsing, compared intra-individually. The mean of all intra-individually compared data was calculated for each treatment group separately. The mean of the treatment groups were compared between the application of OML and placebo on Visit 1 (Day 0) or Visit 3 (V2 + 14 or 21 days), respectively. | |
| End point type | Primary |
| End point timeframe: Bacterial count reduction factor in saliva over 4.5 days of treatment | |

| End point values | OML 0.1%; OML period | OML 0.15%; OML period | OML 0.2%; OML period | OML 0.1%; placebo period |
|--------------------------------------|-------------------------|--------------------------|-------------------------|-----------------------------|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 29 | 29 | 31 | 28 |
| Units: Reduction factor | | | | |
| arithmetic mean (standard deviation) | 3.63 (± 2.11) | 4.30 (± 2.06) | 5.44 (± 2.02) | 0.00 (± 0.70) |

| End point values | OML 0.15%; placebo period | OML 0.2%; placebo period | | |
|--------------------------------------|------------------------------|-----------------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 30 | 30 | | |
| Units: Reduction factor | | | | |
| arithmetic mean (standard deviation) | 0.06 (± 0.73) | 0.05 (± 0.71) | | |

Statistical analyses

| | |
|---|---|
| Statistical analysis title | Primary analysis; OML 0.1% vs placebo |
| Comparison groups | OML 0.1%; placebo period v OML 0.1%, OML period |
| Number of subjects included in analysis | 57 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.0001 |
| Method | ANOVA |

| | |
|---|---|
| Statistical analysis title | Primary analysis; OML 0.15% vs placebo |
| Comparison groups | OML 0.15%; placebo period v OML 0.15%; OML period |
| Number of subjects included in analysis | 59 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.0001 |
| Method | ANOVA |

| | |
|---|---|
| Statistical analysis title | Primary analysis; OML 0.2% vs placebo |
| Comparison groups | OML 0.2%; OML period v OML 0.2%; placebo period |
| Number of subjects included in analysis | 61 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.0001 |
| Method | ANOVA |

Secondary: Plaque index, difference at Day 4

| | |
|-----------------|-----------------------------------|
| End point title | Plaque index, difference at Day 4 |
|-----------------|-----------------------------------|

End point description:

Thickness and extension of plaque were assessed for the "Ramfjord teeth", for each of the 4 surfaces of the teeth, for the upper and lower jaw. The score ranges from 0 (no plaque) to 3 (abundance of soft matter within the gingival pocket and/or on the tooth and gingival margin). The total mean plaque index was the sum of the individual pocket grades divided by the number of investigated sites. The plaque index for each tooth was the sum of the 4 individual grades divided by 4. The total mean plaque index could range from 0 to 3 with higher indices indicating more plaque.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

After a rinsing period of 4 days

| End point values | Placebo | OML 0.1% | OML 0.15% | OML 0.20% |
|--------------------------------------|----------------------|----------------------|----------------------|----------------------|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 88 | 29 | 30 | 31 |
| Units: Score on a scale | | | | |
| arithmetic mean (standard deviation) | 1.58 (± 0.43) | 0.52 (± 0.44) | 0.43 (± 0.34) | 0.42 (± 0.30) |

Statistical analyses

No statistical analyses for this end point

Secondary: Gingival index, mean difference between 2 visits (rinsing period of 4 days)

| | |
|-----------------|---|
| End point title | Gingival index, mean difference between 2 visits (rinsing period of 4 days) |
|-----------------|---|

End point description:

After gingival bleeding was provoked, the gingival index (GI) was assessed for the upper and lower jaw, 4 sites (buccal, mesial, distal, lingual) of the "Ramfjord teeth", with the GI ranking from 0 to 3, with 0 for normal gingiva and 3 for severely inflamed gingiva. For each of the 4 sites a grade from 0 to 3 was given. The total mean GI was the sum of the individual grades divided by the number of investigated sites. The GI for each tooth was the sum of the 4 individual grades divided by 4. The total mean GI could range from 0 to 3 with higher indices indicating a worse gingival condition. The mean difference of GI between 2 visits was assessed. Negative values indicate a worsening of the condition.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Rinsing period of 4 days

| End point values | Placebo | OML 0.1% | OML 0.15% | OML 0.20% |
|--------------------------------------|----------------------|----------------------|----------------------|----------------------|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 88 | 29 | 30 | 31 |
| Units: Score on a scale | | | | |
| arithmetic mean (standard deviation) | -0.24 (± 0.35) | 0.00 (± 0.27) | 0.14 (± 0.24) | 0.12 (± 0.25) |

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Adverse events were collected up to the last dose of study medication in Period 2 plus 14 days.

| | |
|-----------------|----------------|
| Assessment type | Non-systematic |
|-----------------|----------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|----|
| Dictionary version | 17 |
|--------------------|----|

Reporting groups

| | |
|-----------------------|----------------------|
| Reporting group title | OML 0.1%, OML period |
|-----------------------|----------------------|

Reporting group description:

All patients receiving either OML 0.1% in Period 1 followed by placebo in Period 2, or placebo in Period 1 followed by OML 0.1% in Period 2. Data are included for the OML period.

| | |
|-----------------------|--------------------------|
| Reporting group title | OML 0.1%; placebo period |
|-----------------------|--------------------------|

Reporting group description:

All patients receiving either OML 0.1% in Period 1 followed by placebo in Period 2, or placebo in Period 1 followed by OML 0.1% in Period 2. Data from the placebo period are included.

| | |
|-----------------------|-----------------------|
| Reporting group title | OML 0.15%; OML period |
|-----------------------|-----------------------|

Reporting group description:

All patients receiving either OML 0.15% in Period 1 followed by placebo in Period 2, or placebo in Period 1 followed by OML 0.15% in Period 2. Data are included for the OML period.

| | |
|-----------------------|---------------------------|
| Reporting group title | OML 0.15%; placebo period |
|-----------------------|---------------------------|

Reporting group description:

All patients receiving either OML 0.15% in Period 1 followed by placebo in Period 2, or placebo in Period 1 followed by OML 0.15% in Period 2. Data are included for the placebo period.

| | |
|-----------------------|----------------------|
| Reporting group title | OML 0.2%; OML period |
|-----------------------|----------------------|

Reporting group description:

All patients receiving either OML 0.2% in Period 1 followed by placebo in Period 2, or placebo in Period 1 followed by OML 0.2% in Period 2. Data are included for the OML period.

| | |
|-----------------------|--------------------------|
| Reporting group title | OML 0.2%; placebo period |
|-----------------------|--------------------------|

Reporting group description:

All patients receiving either OML 0.2% in Period 1 followed by placebo in Period 2, or placebo in Period 1 followed by OML 0.2% in Period 2. Data are included for the placebo period.

| Serious adverse events | OML 0.1%, OML period | OML 0.1%; placebo period | OML 0.15%; OML period |
|---|----------------------|--------------------------|-----------------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 0 / 29 (0.00%) | 0 / 29 (0.00%) | 0 / 30 (0.00%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | 0 | 0 | 0 |

| Serious adverse events | OML 0.15%; placebo period | OML 0.2%; OML period | OML 0.2%; placebo period |
|---|---------------------------|----------------------|--------------------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 31 (0.00%) | 0 / 31 (0.00%) |
| number of deaths (all causes) | 0 | 0 | 0 |

| | | | |
|--|---|---|---|
| number of deaths resulting from adverse events | 0 | 0 | 0 |
|--|---|---|---|

Frequency threshold for reporting non-serious adverse events: 0 %

| Non-serious adverse events | OML 0.1%, OML period | OML 0.1%; placebo period | OML 0.15%; OML period |
|--|----------------------|--------------------------|-----------------------|
| Total subjects affected by non-serious adverse events subjects affected / exposed | 12 / 29 (41.38%) | 6 / 29 (20.69%) | 11 / 30 (36.67%) |
| Injury, poisoning and procedural complications | | | |
| Thermal burn | | | |
| subjects affected / exposed | 1 / 29 (3.45%) | 0 / 29 (0.00%) | 0 / 30 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Nervous system disorders | | | |
| Burning sensation mucosal | | | |
| subjects affected / exposed | 1 / 29 (3.45%) | 0 / 29 (0.00%) | 1 / 30 (3.33%) |
| occurrences (all) | 1 | 0 | 1 |
| Ageusia | | | |
| subjects affected / exposed | 1 / 29 (3.45%) | 0 / 29 (0.00%) | 0 / 30 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Dysgeusia | | | |
| subjects affected / exposed | 1 / 29 (3.45%) | 0 / 29 (0.00%) | 0 / 30 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Migraine | | | |
| subjects affected / exposed | 0 / 29 (0.00%) | 0 / 29 (0.00%) | 0 / 30 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 0 / 29 (0.00%) | 1 / 29 (3.45%) | 0 / 30 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Lymphadenopathy | | | |
| subjects affected / exposed | 0 / 29 (0.00%) | 0 / 29 (0.00%) | 1 / 30 (3.33%) |
| occurrences (all) | 0 | 0 | 1 |
| General disorders and administration site conditions | | | |
| Device failure | | | |

| | | | |
|--|----------------------|---------------------|----------------------|
| subjects affected / exposed occurrences (all) | 0 / 29 (0.00%) 0 | 1 / 29 (3.45%) 1 | 0 / 30 (0.00%) 0 |
| Gastrointestinal disorders | | | |
| Breath odour | | | |
| subjects affected / exposed occurrences (all) | 0 / 29 (0.00%) 0 | 1 / 29 (3.45%) 1 | 0 / 30 (0.00%) 0 |
| Gingival bleeding | | | |
| subjects affected / exposed occurrences (all) | 1 / 29 (3.45%) 1 | 0 / 29 (0.00%) 0 | 0 / 30 (0.00%) 0 |
| Aphthous stomatitis | | | |
| subjects affected / exposed occurrences (all) | 1 / 29 (3.45%) 1 | 0 / 29 (0.00%) 0 | 0 / 30 (0.00%) 0 |
| Tongue discolouration | | | |
| subjects affected / exposed occurrences (all) | 5 / 29 (17.24%) 5 | 0 / 29 (0.00%) 0 | 5 / 30 (16.67%) 5 |
| Tooth discolouration | | | |
| subjects affected / exposed occurrences (all) | 7 / 29 (24.14%) 7 | 1 / 29 (3.45%) 1 | 6 / 30 (20.00%) 6 |
| Dental caries | | | |
| subjects affected / exposed occurrences (all) | 0 / 29 (0.00%) 0 | 0 / 29 (0.00%) 0 | 0 / 30 (0.00%) 0 |
| Tooth deposit | | | |
| subjects affected / exposed occurrences (all) | 0 / 29 (0.00%) 0 | 0 / 29 (0.00%) 0 | 0 / 30 (0.00%) 0 |
| Gingival inflammation | | | |
| subjects affected / exposed occurrences (all) | 0 / 29 (0.00%) 0 | 0 / 29 (0.00%) 0 | 0 / 30 (0.00%) 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Oropharyngeal pain | | | |
| subjects affected / exposed occurrences (all) | 0 / 29 (0.00%) 0 | 0 / 29 (0.00%) 0 | 0 / 30 (0.00%) 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Pain in jaw | | | |
| subjects affected / exposed occurrences (all) | 0 / 29 (0.00%) 0 | 0 / 29 (0.00%) 0 | 0 / 30 (0.00%) 0 |
| Infections and infestations | | | |

| | | | |
|---|---------------------|---------------------|---------------------|
| Nasopharyngitis subjects affected / exposed occurrences (all) | 2 / 29 (6.90%) 2 | 2 / 29 (6.90%) 2 | 1 / 30 (3.33%) 1 |
| Conjunctivitis subjects affected / exposed occurrences (all) | 0 / 29 (0.00%) 0 | 0 / 29 (0.00%) 0 | 0 / 30 (0.00%) 0 |

| Non-serious adverse events | OML 0.15%; placebo period | OML 0.2%; OML period | OML 0.2%; placebo period |
|---|------------------------------|-------------------------|-----------------------------|
| Total subjects affected by non-serious adverse events subjects affected / exposed | 3 / 30 (10.00%) | 16 / 31 (51.61%) | 4 / 31 (12.90%) |
| Injury, poisoning and procedural complications Thermal burn subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 31 (0.00%) 0 | 0 / 31 (0.00%) 0 |
| Nervous system disorders Burning sensation mucosal subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 31 (0.00%) 0 | 0 / 31 (0.00%) 0 |
| Ageusia subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 31 (0.00%) 0 | 0 / 31 (0.00%) 0 |
| Dysgeusia subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 1 / 31 (3.23%) 1 | 0 / 31 (0.00%) 0 |
| Migraine subjects affected / exposed occurrences (all) | 1 / 30 (3.33%) 1 | 0 / 31 (0.00%) 0 | 0 / 31 (0.00%) 0 |
| Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 31 (0.00%) 0 | 0 / 31 (0.00%) 0 |
| Lymphadenopathy subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 31 (0.00%) 0 | 0 / 31 (0.00%) 0 |
| General disorders and administration site conditions | | | |

| | | | |
|---|---------------------|------------------------|---------------------|
| Device failure subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 31 (0.00%) 0 | 0 / 31 (0.00%) 0 |
| Gastrointestinal disorders | | | |
| Breath odour subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 31 (0.00%) 0 | 0 / 31 (0.00%) 0 |
| Gingival bleeding subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 31 (0.00%) 0 | 0 / 31 (0.00%) 0 |
| Aphthous stomatitis subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 1 / 31 (3.23%) 1 | 0 / 31 (0.00%) 0 |
| Tongue discolouration subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 10 / 31 (32.26%) 10 | 0 / 31 (0.00%) 0 |
| Tooth discolouration subjects affected / exposed occurrences (all) | 1 / 30 (3.33%) 1 | 8 / 31 (25.81%) 8 | 0 / 31 (0.00%) 0 |
| Dental caries subjects affected / exposed occurrences (all) | 1 / 30 (3.33%) 1 | 0 / 31 (0.00%) 0 | 0 / 31 (0.00%) 0 |
| Tooth deposit subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 31 (0.00%) 0 | 1 / 31 (3.23%) 1 |
| Gingival inflammation subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 31 (0.00%) 0 | 1 / 31 (3.23%) 1 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Oropharyngeal pain subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 1 / 31 (3.23%) 1 | 0 / 31 (0.00%) 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Pain in jaw subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 1 / 31 (3.23%) 1 | 0 / 31 (0.00%) 0 |

| | | | |
|--|---------------------|---------------------|---------------------|
| Infections and infestations Nasopharyngitis subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 2 / 31 (6.45%) 2 | 1 / 31 (3.23%) 1 |
| Conjunctivitis subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 31 (0.00%) 0 | 1 / 31 (3.23%) 1 |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

| |
|------|
| None |
|------|

Notes: